Impacts of nanomedicines in ocular pharmacotherapy

BioImpacts

Volumn 1, Issue 1, 2011, Pages 7-22

  Nakhlband, Ailar ^a   Barar, Jaleh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Molecular medicine; Nanomedicine; Nanotechnology; Ocular drug delivery; Ophthalmology

Indexed keywords

AMBISONE; AMPHOTERICIN B; ARTIFICIAL TEAR; BUDESONIDE; CARBOXYLIC ACID; CHITOSAN; CYANOACRYLATE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DENDRIMER; DEXAMETHASONE; DICLOFENAC; DOXORUBICIN; EUDRAGIT; FLURBIPROFEN; GANCICLOVIR; LIPOSOME; METHYLPREDNISOLONE; NANOPARTICLE; NANOSPHERE; PIGMENT EPITHELIUM DERIVED FACTOR; PIROXICAM; POLYACRYLIC ACID; POLYAMIDOAMINE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RHODAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BIOAVAILABILITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOMEDICINE; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; DEACETYLATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; ENDOCYTOSIS; ENDOPHTHALMITIS; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; GLAUCOMA; GLIA CELL; HUMAN; HYDROGEL; HYDROLYSIS; IMMUNOGENICITY; INTRAOCULAR PRESSURE; IONIZATION; LACRIMATION; LASER COAGULATION; LIPID BILAYER; NANOMEDICINE; NERVE DEGENERATION; NONHUMAN; OPHTHALMOLOGY; PHOTODYNAMIC THERAPY; PREVENTIVE MEDICINE; RETINA GANGLION CELL; SCANNING ELECTRON MICROSCOPY; SUBRETINAL NEOVASCULARIZATION; TISSUE ENGINEERING; TOXICOGENETICS; TRANSLATIONAL RESEARCH; UVEORETINITIS; VASCULAR ENDOTHELIUM;

EID: 84876715577     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2011.003     Document Type: Article

References (91)

1. Adibkia K, Omidi Y, Siahi MR, Javadzadeh AR, Barzegar-Jalali M, Barar J et al. 2007a. Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in Rabbits. J Ocul Pharmacol Ther, 23(5), 421-432.
2. Adibkia K, Siahi Shadbad MR, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M, Barar J et al. 2007b. Piroxicam Nanoparticles for Ocular Delivery: Physicochemical Characterization and Implementation in Endotoxin-Induced Uveitis. J Drug Target, 15(6), 407-416.
3. Agnihotri SM and Vavia PR. 2009. Diclofenac-Loaded Biopolymeric Nanosuspensions for Ophthalmic Application. Nanomedicine, 5(1), 90-95.
4. Asrani S, Goldberg MF and Zeimer R. 2006. Thermal-Sensitive Liposomes, In: Intraocular Drug Delivery, Jaffe GJ, Ashton P, Pearson PA, Eds. Taylor & Francis Group, LLC, New York, pp 143-156.
5. Athanasiou KA, Niederauer GG and Agrawal CM. 1996. Sterilization, Toxicity, Biocompatibility and Clinical Applications of Polylactic Acid/Polyglycolic Acid Copolymers. Biomaterials, 17(2), 93-102.
6. Attar M, Shen J, Ling KH and Tang-Liu D. 2005. Ophthalmic Drug Delivery Considerations at the Cellular Level: Drug-Metabolising Enzymes and Transporters. Expert Opin Drug Deliv, 2(5), 891-908.
7. Auricchio A. 2003. Pseudotyped AAV Vectors for Constitutive and Regulated Gene Expression in the Eye. Vision Res, 43(8), 913-918.
8. Auricchio A, Rivera VM, Clackson T, O'Connor EE, Maguire AM, Tolentino MJ et al. 2002. Pharmacological Regulation of Protein Expression From Adeno-Associated Viral Vectors in the Eye. Mol Ther, 6(2), 238-242.
9. Badawi AA, El-Laithy HM, El Qidra RK, El MH and El dM. 2008. Chitosan Based Nanocarriers for Indomethacin Ocular Delivery. Arch Pharm Res, 31(8), 1040-1049.
10. Bainbridge, J. W.; Ali, R. R. Ocular gene therapy trials due to report this year; Keeping an eye on clinical trials in 2008. Gene Ther. 2008.
11. Bainbridge JW, Tan MH and Ali RR. 2006. Gene Therapy Progress and Prospects: the Eye. Gene Ther, 13(16), 1191-1197.
12. Bakri SJ and Kaiser PK. 2006. Antiangiogenic Agents: Intravitreal Injection, In: Intraocular Drug Delivery, Jaffe GJ, Ashton P, Pearson PA, Eds. Taylor & Francis Group, LLC, New York, pp 71-84.
13. Barar J, Asadi M, Mortazavi-Tabatabaei SA and Omidi Y. 2009. Ocular Drug Delivery: Impact of in Vitro Cell Culture Models. J Ophth Vision Res, 4(4), 238-252.
14. Barar J, Javadzadeh AR and Omidi Y. 2008. Ocular Novel Drug Delivery: Impacts of Membranes and Barriers. Expert Opin Drug Deliv, 5(5), 567-581.
15. Barar J and Omidi Y. 2008. Bioelectrical and Permeability Properties of Brain Microvasculature Endothelial Cells: Effects of Tight Junction Modulators. Journal of Biological Sciences, 8(3), 556-562.
16. Barza M, Stuart M and Szoka F, Jr. 1987. Effect of Size and Lipid Composition on the Pharmacokinetics of Intravitreal Liposomes. Invest Ophthalmol Vis Sci, 28(5), 893-900.
17. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC et al. 2005. Nanoparticles for Gene Delivery to Retinal Pigment Epithelial Cells. Mol Vis, 11), 124-132.
18. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D and Behar-Cohen F. 2006. Non-Viral Ocular Gene Therapy: Potential Ocular Therapeutic Avenues. Adv Drug Deliv Rev, 58(11), 1224-1242.
19. Bu HZ, Gukasyan HJ, Goulet L, Lou XJ, Xiang C and Koudriakova T. 2007. Ocular Disposition, Pharmacokinetics, Efficacy and Safety of Nanoparticle-Formulated Ophthalmic Drugs. Curr Drug Metab, 8(2), 91-107.
20. Bucolo C, Maltese A, Maugeri F, Busa B, Puglisi G and Pignatello R. 2004. Eudragit RL100 Nanoparticle System for the Ophthalmic Delivery of Cloricromene. J Pharm Pharmacol, 56(7), 841-846.
21. Calvo P, Alonso MJ, Vila-Jato JL and Robinson JR. 1996. Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers. J Pharm Pharmacol, 48(11), 1147-1152.
22. Camelo S, Lajavardi L, Bochot A, Goldenberg B, Naud MC, Brunel N et al. 2009. Protective Effect of Intravitreal Injection of Vasoactive Intestinal Peptide-Loaded Liposomes on Experimental Autoimmune Uveoretinitis. J Ocul Pharmacol Ther, 25(1), 9-21.
23. Conrad JM and Robinson JR. 1977. Aqueous Chamber Drug Distribution Volume Measurement in Rabbits. J Pharm Sci, 66(2), 219-224.
24. Cunha-Vaz JG. 1997a. The Blood-Ocular Barriers: Past, Present, and Future. Doc Ophthalmol, 93(1-2), 149-157.
25. Cunha-Vaz JG. 1997b. The Blood-Ocular Barriers: Past, Present, and Future. Doc Ophthalmol, 93(1-2), 149-157.
26. De Campos AM, Diebold Y, Carvalho EL, Sanchez A and Alonso MJ. 2004. Chitosan Nanoparticles As New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity. Pharm Res, 21(5), 803-810.
27. De Campos AM, Sanchez A and Alonso MJ. 2001. Chitosan Nanoparticles: a New Vehicle for the Improvement of the Delivery of Drugs to the Ocular Surface. Application to Cyclosporin A. Int J Pharm, 224(1-2), 159-168.
28. Dillen K, Vandervoort J, Van den Mooter G and Ludwig A. 2006. Evaluation of Ciprofloxacin-Loaded Eudragit RS100 or RL100/PLGA Nanoparticles. Int J Pharm, 314(1), 72-82.
29. Dong X, Shi W, Yuan G, Xie L, Wang S and Lin P. 2006. Intravitreal Implantation of the Biodegradable Cyclosporin A Drug Delivery System for Experimental Chronic Uveitis. Graefes Arch Clin Exp Ophthalmol, 244(4), 492-497.
30. Duan X and Sheardown H. 2006. Dendrimer Crosslinked Collagen As a Corneal Tissue Engineering Scaffold: Mechanical Properties and Corneal Epithelial Cell Interactions. Biomaterials, 27(26), 4608-4617.
31. Duvvuri S, Majumdar S and Mitra AK. 2003. Drug Delivery to the Retina: Challenges and Opportunities. Expert Opin Biol Ther, 3(1), 45-56.
32. Duvvuri S, Majumdar S and Mitra AK. 2004. Role of Metabolism in Ocular Drug Delivery. Curr Drug Metab, 5(6), 507-515.
33. Fenwick BW and Cullis PR. 2008. Liposomal Nanomedicines. Expert Opin Drug Deliv, 5(1), 25-44.
34. Fischbarg J. 2006. The Biology of the Eye. Elsevier Science, Amsterdam.
35. Frank RG. 2003. New Estimates of Drug Development Costs. J Health Econ, 22(2), 325-330.
36. Freddo TF. 2001. Shifting the Paradigm of the Blood-Aqueous Barrier. Exp Eye Res, 73(5), 581-592.
37. Gardner TW, Antonetti DA, Barber AJ, Lieth E and Tarbell JA. 1999. The Molecular Structure and Function of the Inner Blood-Retinal Barrier. Penn State Retina Research Group. Doc Ophthalmol, 97(3-4), 229-237.
38. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G et al. 2003. Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability. Pharm Res, 20(4), 584-590.
39. Hamilton MM, Brough DE, McVey D, Bruder JT, King CR and Wei LL. 2006. Repeated Administration of Adenovector in the Eye Results in Efficient Gene Delivery. Invest Ophthalmol Vis Sci, 47(1), 299-305.
40. Hayek S, Scherrer M, Barthelmes D, Fleischhauer JC, Kurz-Levin MM, Menghini M et al. 2007. First Clinical Experience With Anecortave Acetate (Retaane). Klin Monatsbl Augenheilkd, 224(4), 279-281.
41. Herrero-Vanrell R and Refojo MF. 2001. Biodegradable Microspheres for Vitreoretinal Drug Delivery. Adv Drug Deliv Rev, 52(1), 5-16.
42. Hillaireau H, Le DT and Couvreur P. 2006. Polymer-Based Nanoparticles for the Delivery of Nucleoside Analogues. J Nanosci Nanotechnol, 6(9-10), 2608-2617.
43. Jabs DA. 1995. Controversies in the Treatment of Cytomegalovirus Retinitis: Foscarnet Versus Ganciclovir. Infect Agents Dis, 4(3), 131-142.
44. Janoria KG, Gunda S, Boddu SH and Mitra AK. 2007. Novel Approaches to Retinal Drug Delivery. Expert Opin Drug Deliv, 4(4), 371-388.
45. Janzer RC and Raff MC. 1987. Astrocytes Induce Blood-Brain Barrier Properties in Endothelial Cells. Nature, 325(6101), 253-257.
46. Jose Alonso M. 2004. Nanomedicines for Overcoming Biological Barriers. Biomedecine & Pharmacotherapy, 58(3), 168-172.
47. Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G et al. 2008. Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization. Invest Ophthalmol Vis Sci, 49(2), 662-670.
48. Kassem MA, bdel Rahman AA, Ghorab MM, Ahmed MB and Khalil RM. 2007. Nanosuspension As an Ophthalmic Delivery System for Certain Glucocorticoid Drugs. Int J Pharm, 340(1-2), 126-480.
49. Kaur IP, Garg A, Singla AK and Aggarwal D. 2004. Vesicular Systems in Ocular Drug Delivery: an Overview. Int J Pharm, 269(1), 1-14.
50. Kayser O, Lemke A and Hernandez-Trejo N. 2005. The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems. Curr Pharm Biotechnol, 6(1), 3-5.
51. Kimura H and Ogura Y. 2001. Biodegradable Polymers for Ocular Drug Delivery. Ophthalmologica, 215(3), 143-155.
52. Kobayashi H, Shiraki K and Ikada Y. 1992. Toxicity Test of Biodegradable Polymers by Implantation in Rabbit Cornea. J Biomed Mater Res, 26(11), 1463-1476.
53. Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A et al. 2003. Contribution of TNF-Alpha to Leukocyte Adhesion, Vascular Leakage, and Apoptotic Cell Death in Endotoxin-Induced Uveitis in Vivo. Invest Ophthalmol Vis Sci, 44(5), 2184-2191.
54. Lang JC. 1995. Ocular Drug Delivery Conventional Ocular Formulation. Adv Drug Deliv Rev, 16), 39-43.
55. Lazic R and Gabric N. 2007. Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization Due to Age-Related Macular Degeneration. Ophthalmology, 114(6), 1179-1185.
56. Le MG, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D et al. 2007. Restoration of Vision in RPE65-Deficient Briard Dogs Using an AAV Serotype 4 Vector That Specifically Targets the Retinal Pigmented Epithelium. Gene Ther, 14(4), 292-303.
57. Li H, Tran VV, Hu Y, Mark SW, Barnstable CJ and Tombran-Tink J. 2006. A PEDF N-Terminal Peptide Protects the Retina From Ischemic Injury When Delivered in PLGA Nanospheres. Exp Eye Res, 83(4), 824-833.
58. Liu D, Ren T and Gao X. 2003. Cationic Transfection Lipids. Curr Med Chem, 10(14), 1307-1315.
59. Loutsch JM, Ong D and Hill JM. 2003. Dendrimers: An Innovative and Enhanced Ocular Drug Delivery System, In: Ophthalmic Drug Delivery Systems, Mitra AK, Ed. Marcel Dekker, Inc., New York, pp 467-492.
60. Maguire AM and Bennett J. 2006. Gene Therapy for Retinal Disease, In: Intraocular Drug Delivery, Jaffe GJ, Ashton P, Pearson PA, Eds. Taylor & Francis Group, LLC, New York, pp 157-173.
61. Majidi J, Barar J, Baradaran B, Abdolalizadeh J and Omidi Y. 2009. Target Therapy of Cancer: Implementation of Monoclonal Antibodies and Nanobodies. Hum Antibodies, 18(3), 81-100.
62. Marano RJ, Toth I, Wimmer N, Brankov M and Rakoczy PE. 2005. Dendrimer Delivery of an Anti-VEGF Oligonucleotide into the Eye: a Long-Term Study into Inhibition of Laser-Induced CNV, Distribution, Uptake and Toxicity. Gene Ther, 12(21), 1544-1550.
63. Marie O, Thillaye-Goldenberg B, Naud MC and de Kozak Y. 1999. Inhibition of Endotoxin-Induced Uveitis and Potentiation of Local TNF-Alpha and Interleukin-6 MRNA Expression by Interleukin-13. Invest Ophthalmol Vis Sci, 40(10), 2275-82.
64. Mitra AK, Anand BS and Duvvuri S. 2006. Drug Delivery to the Eye, In: The Biology of Eye, Fischbarg J, Ed. Academic Press, New York, pp 307-351.
65. Muccioli C and Belfort R, Jr. 2000. Treatment of Cytomegalovirus Retinitis With an Intraocular Sustained-Release Ganciclovir Implant. Braz J Med Biol Res, 33(7), 779-789.
66. Muyldermans S, Baral TN, Retamozzo VC, De BP, De GE, Kinne J et al. 2009. Camelid Immunoglobulins and Nanobody Technology. Vet Immunol Immunopathol, 128(1-3), 178-660.
67. ndrieu-Soler C, Bejjani RA, de BT, Normand N, BenEzra D and Behar-Cohen F. 2006. Ocular Gene Therapy: a Review of Nonviral Strategies. Mol Vis, 12), 1334-1347.
68. Nicolazzi C, Garinot M, Mignet N, Scherman D and Bessodes M. 2003. Cationic Lipids for Transfection. Curr Med Chem, 10(14), 1263-1277.
69. Nishiyama N, Iriyama A, Jang WD, Miyata K, Itaka K, Inoue Y et al. 2005. Light-Induced Gene Transfer From Packaged DNA Enveloped in a Dendrimeric Photosensitizer. Nat Mater, 4(12), 934-941.
70. Omidi Y, Barar J, Ahmadian S, Heidari HR and Gumbleton M. 2008. Characterization and Astrocytic Modulation of System L Transporters in Brain Microvasculature Endothelial Cells. Cell Biochem Funct, 26(3), 381-391.
71. Omidi Y, Barar J and Akhtar S. 2005. Toxicogenomics of Cationic Lipid-Based Vectors for Gene Therapy: Impact of Microarray Technology. Curr Drug Deliv, 2(4), 429-441.
72. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S and Gumbleton M. 2003. Evaluation of the Immortalised Mouse Brain Capillary Endothelial Cell Line, B.End3, As an in Vitro Blood-Brain Barrier Model for Drug Uptake and Transport Studies. Brain Res, 990(1-2), 95-720.
73. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF and Akhtar S. 2003b. Toxicogenomics of Non-Viral Vectors for Gene Therapy: a Microarray Study of Lipofectin- and Oligofectamine-Induced Gene Expression Changes in Human Epithelial Cells. J Drug Target, 11(6), 311-323.
74. Patravale VB, Date AA and Kulkarni RM. 2004. Nanosuspensions: a Promising Drug Delivery Strategy. J Pharm Pharmacol, 56(7), 827-840.
75. Pece A, Isola V, Vadala M and Calori G. 2007. Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Associated With Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration. Retina, 27(3), 342-348.
76. Pedroso de Lima MC, Simoes S, Pires P, Faneca H and Duzgunes N. 2001. Cationic Lipid-DNA Complexes in Gene Delivery: From Biophysics to Biological Applications. Adv Drug Deliv Rev, 47(2-3), 277-760.
77. Peeters L, Sanders NN, Braeckmans K, Boussery K, Van d, V, De Smedt SC et al. 2005. Vitreous: a Barrier to Nonviral Ocular Gene Therapy. Invest Ophthalmol Vis Sci, 46(10), 3553-3561.
78. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A and Puglisi G. 2002. Eudragit RS100 Nanosuspensions for the Ophthalmic Controlled Delivery of Ibuprofen. Eur J Pharm Sci, 16(1-2), 53-780.
79. Pignatello R, Bucolo C, Spedalieri G, Maltese A and Puglisi G. 2002b. Flurbiprofen-Loaded Acrylate Polymer Nanosuspensions for Ophthalmic Application. Biomaterials, 23(15), 3247-3255.
80. Rose RC and Bode AM. 1991. Ocular Ascorbate Transport and Metabolism. Comparative Biochemistry and Physiology Part A: Physiology, 100(2), 273-285.
81. Sahoo SK, Dilnawaz F and Krishnakumar S. 2008. Nanotechnology in Ocular Drug Delivery. Drug Discov Today, 13(3-4), 144-810.
82. Sanders NN, Peeters L, Lentacker I, Demeester J and De Smedt SC. 2007. Wanted and Unwanted Properties of Surface PEGylated Nucleic Acid Nanoparticles in Ocular Gene Transfer. J Control Release, 122(3), 226-235.
83. Selvin BL. 1983. Systemic Effects of Topical Ophthalmic Medications. South Med J, 76(3), 349-358.
84. Smith M, Omidi Y and Gumbleton M. 2007. Primary Porcine Brain Microvascular Endothelial Cells: Biochemical and Functional Characterisation As a Model for Drug Transport and Targeting. J Drug Target, 15(4), 253-268.
85. Tao W, Wen R, Laties A and Aguirre GD. 2006. Cell-Based Delivery Systems:Development of Encapsulated Cell Technology for Ophthalmic Applications, In: Intraocular Drug Delivery, Jaffe GJ, Ashton P, Pearson PA, Eds. Taylor & Francis Group, LLC, New York, pp 111-128.
86. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S et al. 1984. New Class of Polymers: Starburst-Dendritic Macromolecules. Polymer Journal, 17(1), 117-132.
87. Urtti A. 2006. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery. Adv Drug Deliv Rev, 58(11), 1131-1135.
88. Vandamme TF and Brobeck L. 2005. Poly(Amidoamine) Dendrimers As Ophthalmic Vehicles for Ocular Delivery of Pilocarpine Nitrate and Tropicamide. J Control Release, 102(1), 23-38.
89. Vandervoort J and Ludwig A. 2007. Ocular Drug Delivery: Nanomedicine Applications. Nanomed, 2(1), 11-21.
90. Vega E, Egea MA, Valls O, Espina M and Garcia ML. 2006. Flurbiprofen Loaded Biodegradable Nanoparticles for Ophtalmic Administration. J Pharm Sci, 95(11), 2393-2405.
91. Zimmer A and Kreuter J. 1995. Microspheres and Nanoparticles Used in Ocular Delivery Systems. Adv Drug Deliv Rev, 16), 61-73.